187 related articles for article (PubMed ID: 27521286)
1. Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration-resistant prostate cancer.
Jeong Y; Lee JL
Asia Pac J Clin Oncol; 2017 Jun; 13(3):204-211. PubMed ID: 27521286
[TBL] [Abstract][Full Text] [Related]
2. Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.
Yashi M; Nishihara D; Mizuno T; Yuki H; Masuda A; Kambara T; Betsunoh H; Abe H; Fukabori Y; Muraishi O; Kamai T
Clin Genitourin Cancer; 2014 Oct; 12(5):e197-203. PubMed ID: 24674784
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L; Galli L; Orlandi P; Fioravanti A; Di Desidero T; Fontana A; Antonuzzo A; Biasco E; Farnesi A; Marconcini R; Francia G; Danesi R; Falcone A; Bocci G
Cancer; 2014 Dec; 120(24):3923-31. PubMed ID: 25111199
[TBL] [Abstract][Full Text] [Related]
4. Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Barroso-Sousa R; da Fonseca LG; Souza KT; Chaves AC; Kann AG; de Castro G; Dzik C
Med Oncol; 2015 Jan; 32(1):443. PubMed ID: 25519824
[TBL] [Abstract][Full Text] [Related]
5. Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.
Dabkara D; Ganguly S; Biswas B; Ghosh J
Indian J Cancer; 2018; 55(1):94-97. PubMed ID: 30147102
[TBL] [Abstract][Full Text] [Related]
6. Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs.
Calvani N; Morelli F; Naglieri E; Gnoni A; Chiuri VE; Orlando L; Fedele P; Cinieri S
Med Oncol; 2019 Aug; 36(9):80. PubMed ID: 31399784
[TBL] [Abstract][Full Text] [Related]
7. [Metronomic chemotherapy with oral cyclophosphamide : An individual option for the metastatic castration-resistant prostate cancer patient?].
Knipper S; Mandel P; V Amsberg G; Strölin P; Graefen M; Steuber T
Urologe A; 2019 Apr; 58(4):410-417. PubMed ID: 29808369
[TBL] [Abstract][Full Text] [Related]
8. Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
Di Desidero T; Derosa L; Galli L; Orlandi P; Fontana A; Fioravanti A; Marconcini R; Giorgi M; Campi B; Saba A; Lucchesi S; Felipetto R; Danesi R; Francia G; Allegrini G; Falcone A; Bocci G
Invest New Drugs; 2016 Dec; 34(6):760-770. PubMed ID: 27557783
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
Jpn J Clin Oncol; 2017 Mar; 47(3):247-251. PubMed ID: 28042138
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M; Horvath R; Becht E; Rozkova D; Bilkova P; Sochorova K; Hromadkova H; Kayserova J; Vavrova K; Lastovicka J; Vrabcova P; Kubackova K; Gasova Z; Jarolim L; Babjuk M; Spisek R; Bartunkova J; Fucikova J
Oncotarget; 2015 Jul; 6(20):18192-205. PubMed ID: 26078335
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Caffo O; Facchini G; Biasco E; Ferraù F; Morelli F; Donini M; Buttigliero C; Calvani N; Guida A; Chiuri VE; Basso U; Mucciarini C; Conteduca V; Rossetti S; Veccia A; Maines F; Kinspergher S; De Giorgi U
Future Oncol; 2019 Apr; 15(10):1115-1123. PubMed ID: 30887825
[TBL] [Abstract][Full Text] [Related]
12. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
Int J Urol; 2019 Aug; 26(8):797-803. PubMed ID: 31055879
[TBL] [Abstract][Full Text] [Related]
15. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.
Barata PC; Cooney M; Mendiratta P; Gupta R; Dreicer R; Garcia JA
Invest New Drugs; 2019 Apr; 37(2):331-337. PubMed ID: 30402678
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
Van Praet C; Rottey S; Van Hende F; Pelgrims G; Demey W; Van Aelst F; Wynendaele W; Gil T; Schatteman P; Filleul B; Schallier D; Machiels JP; Schrijvers D; Everaert E; D'Hondt L; Werbrouck P; Vermeij J; Mebis J; Clausse M; Rasschaert M; Van Erps J; Verheezen J; Van Haverbeke J; Goeminne JC; Lumen N
Urol Oncol; 2016 Jun; 34(6):254.e7-254.e13. PubMed ID: 26850781
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Parimi S; Eliasziw M; North S; Trudeau M; Winquist E; Chi KN; Ruether D; Cheng T; Eigl BJ
Invest New Drugs; 2016 Dec; 34(6):771-776. PubMed ID: 27565809
[TBL] [Abstract][Full Text] [Related]
19. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
